IGM Biosciences Terminates and Enters New Material Agreements
| Field | Detail |
|---|---|
| Company | Igm Biosciences, Inc. |
| Form Type | 8-K |
| Filed Date | May 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
IGM Biosciences just changed up some major deals, filing an 8-K today.
AI Summary
IGM Biosciences, Inc. announced on May 23, 2025, the termination of a material definitive agreement. The company also entered into a new material definitive agreement. Financial statements and exhibits related to these events were filed as part of this 8-K report.
Why It Matters
This filing indicates a significant shift in IGM Biosciences' contractual relationships, which could impact its ongoing operations, partnerships, and future strategic direction.
Risk Assessment
Risk Level: medium — The termination and entry into new material definitive agreements suggest potential changes in business strategy or partnerships that could carry inherent risks.
Key Numbers
- 001-39045 — SEC File Number (Identifies the company's filing with the SEC.)
- 77-0349194 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- IGM Biosciences, Inc. (company) — Registrant
- May 23, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 325 E. Middlefield Road, Mountain View, California 94043 (address) — Principal Executive Offices
- Palingen, Inc. (company) — Former Company Name
FAQ
What was the nature of the material definitive agreement that was terminated?
The filing does not specify the nature of the terminated material definitive agreement, only that it occurred on or before May 23, 2025.
What is the nature of the new material definitive agreement entered into by IGM Biosciences?
The filing does not provide details on the specific terms or nature of the new material definitive agreement.
When did the events reported in this 8-K filing occur?
The earliest event reported occurred on May 23, 2025.
What is IGM Biosciences' principal business address?
IGM Biosciences' principal executive offices are located at 325 E. Middlefield Road, Mountain View, California 94043.
Has IGM Biosciences undergone a name change previously?
Yes, IGM Biosciences was formerly known as Palingen, Inc., with a name change date of July 12, 2010.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 29, 2025 regarding IGM Biosciences, Inc..